Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00VMA
|
|||
| Former ID |
DIB014504
|
|||
| Drug Name |
Vatreptacog alfa (activated)
|
|||
| Synonyms |
NN-1731; NNC-0078-0000-0007; Recombinant factor VIIa analog with mutations V158D/E296V/M298Q (bleeding disorders), Novo Nordisk
Click to Show/Hide
|
|||
| Indication | Bleeding disorder [ICD-11: GA20-GA21; ICD-10: R58] | Phase 3 | [1] | |
| Company |
Novo Nordisk A/S
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01392547) Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors. U.S. National Institutes of Health. | |||
| REF 2 | Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial. J Thromb Haemost. 2012 Jan;10(1):81-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.